The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Sandeep, Rendón-Ramírez, Adela, Ásgeirsson, Bjarni, Dutta, Mouparna, Ghosh, Anindya S., Oda, Masataka, Venkatramani, Ravindra, Rao, Basuthkar J., Dandekar, Abhaya M., Goñi, Félix M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309170/
https://www.ncbi.nlm.nih.gov/pubmed/25671081
http://dx.doi.org/10.12688/f1000research.2-286.v3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309170/
https://www.ncbi.nlm.nih.gov/pubmed/25671081
http://dx.doi.org/10.12688/f1000research.2-286.v3

Ejemplares similares